KOL Views: Does Roche’s RG7716 have what it takes to unseat Regeneron’s Eylea?

Roche reported Phase II BOULEVARD results showing RG7716, a bispecific antibody against VEGF and ANG-2, significantly improved best-corrected visual acuity (BCVA) – the primary endpoint – compared to Lucentis (ranibizumab) in patients with diabetic macular oedema (DME). (See ViewPoints: Roche's RG7716 is better than Lucentis – but what about Eylea?)

To provide FirstWord readers with rapid feedback on RG7716’s competitive profile, we are hosting an expert call with a key opinion leader (KOL) early next week.

Key topics that will be discussed during the call include, among other things… feedback on RG7716’s risk/benefit profile based on the BOULEVARD results; how impressive is its 3.6-letter improvement on BCVA versus Lucentis at 24 weeks; if RG7716 demonstrates similar efficacy in Phase III testing, how would its profile compare to that of Eylea in DME; any reason to think RG7716 might be relatively better or worse in wet age-related macular degeneration (AMD); how is it likely to fit in with other possible competitors in the retinal disease space, such as Novartis’ brolucizumab, Allergan/Molecular Partners’ abicipar pegol and/or Eylea biosimilars; are you aware of the recent “spike” in reports of intraocular inflammation tied to Eylea in the FDA’s adverse event database and might this play into how receptive physicians are to trying alternative therapies for retinal diseases?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the evolving treatment paradigm for DME and other retinal diseases.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.